Skip to main content
. 2016 Jan 22;48(1):e205. doi: 10.1038/emm.2015.100

Figure 4.

Figure 4

The CB2 receptor attenuates MPTP-induced astroglial activation and expression of myeloperoxidase (MPO) in the SN in vivo. The SN tissues obtained from the same animals used in Figure 3 were immunostained with a GFAP antibody to label astrocytes (a–f) and with an MPO antibody to evaluate MPO immunoreactivity (g–l). Animals that received PBS as a control (a, g); MPTP (b, h); MPTP and WIN55,212-2 (c, i); MPTP and JWH-133 (d, j); MPTP, WIN55,212-2 and AM630 (e, k); or MPTP, JWH-133 and AM630 (f, l) were killed 3 days after the last MPTP injection. Insets show higher magnifications of a–l. Dotted lines indicate the SNpc. (m) The number of MPO-positive cells in the SN was counted. Four to five animals were used for each experimental group. C, control; M, MPTP; MW, MPTP and WIN55,212-2; MJ, MPTP and JWH-133; MWA, MPTP and WIN55,212-2 and AM630; MJA, MPTP and JWH-133 and AM630. ***P<0.001 significantly different from controls; ##P<0.01 and ###P<0.001 significantly different from MPTP only; $$P<0.01, significantly different from MW. &&P<0.01 significantly different from MJ (ANOVA and Student–Neuman–Keuls analysis). (n) Localization of MPO immunoreactivity in GFAP+ activated astrocytes in the MPTP-treated SN. The SN tissues obtained from the same animals used in b were simultaneously immunostained with antibodies against MPO and GFAP, as a marker for astrocytes. Scale bars: a–l, 200 μm.